Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

  • Either nonselective β-blockers or esophageal variceal ligation can be first-line treatment for primary prophylaxis of variceal hemorrhage in patients with medium to large esophageal and high-risk small varices.
  • Endoscopic variceal ligation is an alternative to pharmacologic therapy for patients intolerant to β-blockers
  • Management of acute variceal hemorrhage includes resuscitation, antibiotic prophylaxis, use of vasoactive agents, and endoscopic treatment with band ligation.
  • Balloon tamponade can be used as a bridge to transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt therapy.
  • Hepatic venous pressure gradient (HVPG) measurements have prognostic and therapeutic value.
  • TIPS, surgical shunt procedures, or liver transplantation are treatment options for patients who do not respond to medical therapy.
  • Gastric varices that are contiguous with esophageal varices can be treated as esophageal varices; those below the gastroesophageal junction are best treated with endoscopic injection of glue.
  • TIPS is the preferred rescue procedure for uncontrolled variceal bleeding and can be first line therapy for high risk patients.
  • Portal hypertensive gastropathy is usually mild and stops spontaneously.
  • Chronic bleeding from portal hypertensive gastropathy is treated with β-blockers or TIPS based on the severity of hemorrhage.

Chronic liver disease and cirrhosis are the 12th-leading causes of mortality in the United States. Portal hypertension and its consequences are progressively debilitating complications of cirrhosis (Table 47–1). Variceal hemorrhage, spontaneous bacterial peritonitis, and the hepatorenal syndrome are chiefly responsible for the high morbidity and mortality rates in patients with cirrhosis.

Table 47–1. Causes of Portal Hypertension.

Esophageal varices develop at a rate of 5–8% per year in patients with cirrhosis and portal hypertension, and up to 80% of patients with cirrhosis will eventually develop this complication. Variceal hemorrhage occurs in 25–35% of patients with cirrhosis and large esophagogastric varices. The majority of bleeding episodes occur within the first year of diagnosis of varices. Bleeding from esophageal varices is associated with 15–20% early mortality and accounts for one-third of all deaths. If no long-term therapy is instituted after control of acute hemorrhage, 60–70% of patients will experience recurrent variceal hemorrhage. Most of these episodes occur within 6 months of the index bleed.

Portal hypertension develops as a result of two main factors: (1) an increase ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.